|
1
|
Palmerini E, Staals EL, Alberghini M,
Zanella L, Ferrari C, Benassi MS, Picci P, Mercuri M, Bacci G and
Ferrari S: Synovial sarcoma: Retrospective analysis of 250 patients
treated at a single institution. Cancer. 115:2988–2998. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bergh P, Meis-Kindblom JM, Gherlinzoni F,
Berlin O, Bacchini P, Bertoni F, Gunterberg B and Kindblom LG:
Synovial sarcoma: Identification of low and high risk groups.
Cancer. 85:2596–2607. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baccari-Ezzine S, Chelbi E and Bouzaidi K:
Intracardiac metastasis of primary synovial sarcoma of the lung.
Asian Cardiovasc Thorac Ann. 21:623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Amankwah EK, Conley AP and Reed DR:
Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol.
5:147–162. 2013.PubMed/NCBI
|
|
5
|
Wushou A and Miao XC: Tumor size predicts
prognosis of head and neck synovial cell sarcoma. Oncol Lett.
9:381–386. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bakri A, Shinagare AB, Krajewski KM,
Howard SA, Jagannathan JP, Hornick JL and Ramaiya NH: Synovial
sarcoma: Imaging features of common and uncommon primary sites,
metastatic patterns, and treatment response. AJR Am J Roentgenol.
199:208–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bhan A, Soleimani M and Mandal SS: Long
Noncoding RNA and Cancer: A new paradigm. Cancer Res. 77:3965–3981.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hon CC, Ramilowski JA, Harshbarger J,
Bertin N, Rackham OJ, Gough J, Denisenko E, Schmeier S, Poulsen TM,
Severin J, et al: An atlas of human long non-coding RNAs with
accurate 5′ends. Nature. 543:199–204. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chandra Gupta S and Nandan Tripathi Y:
Potential of long non-coding RNAs in cancer patients: From
bio-markers to therapeutic targets. Int J Cancer. 140:1955–1967.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rao AKDM, Rajkumar T and Mani S:
Perspectives of long non-coding RNAs in cancer. Mol Biol Rep.
44:203–218. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu L, Cui S, Wan T, Li X, Tian W, Zhang
R, Luo L and Shi Y: Long non-coding RNA HOTAIR acts as a competing
endogenous RNA to promote glioma progression by sponging
miR-126-5p. J Cell Physiol. 233:6822–6831. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kogo R, Shimamura T, Mimori K, Kawahara K,
Imoto S, Sudo T, Tanaka F, Shibata K, Suzuki A, Komune S, et al:
Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin
modification and is associated with poor prognosis in colorectal
cancers. Cancer Res. 71:6320–6326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim K, Jutooru I, Chadalapaka G, Johnson
G, Frank J, Burghardt R, Kim S and Safe S: HOTAIR is a negative
prognostic factor and exhibits pro-oncogenic activity in pancreatic
cancer. Oncogene. 32:1616–1625. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang Z, Zhou L, Wu LM, Lai MC, Xie HY,
Zhang F and Zheng SS: Overexpression of long Non-coding RNA HOTAIR
predicts tumor recurrence in hepatocellular carcinoma patients
following liver transplantation. Ann Surg Oncol. 18:1243–1250.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nie Y, Liu X, Qu S, Song E, Zou H and Gong
C: Long non-coding RNA HOTAIR is an independent prognostic marker
for nasopharyngeal carcinoma progression and survival. Cancer Sci.
104:458–464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim HJ, Lee DW, Yim GW, Nam EJ, Kim S, Kim
SW and Kim YT: Long non-coding RNA HOTAIR is associated with human
cervical cancer progression. Int J Oncol. 46:521–530. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yan J, Dang Y, Liu S, Zhang Y and Zhang G:
LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by
targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumor Biol.
Nov 30–2016.(Epub ahead of print). doi: 10.1007/s13277-016-5448-5.
View Article : Google Scholar
|
|
19
|
Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y,
Li C, Chong M, Ibrahim T, Mercatali L, et al: miR-126 and miR-126*
repress recruitment of mesenchymal stem cells and inflammatory
monocytes to inhibit breast cancer metastasis. Nat Cell Biol.
15:284–294. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Feng Q, Guo P, Wang J, Zhang X, Yang HC
and Feng JG: High expression of SDF-1 and VEGF is associated with
poor prognosis in patients with synovial sarcomas. Exp Ther Med.
15:2597–2603. 2018.PubMed/NCBI
|
|
21
|
Tanaka K and Ozaki T: New TNM
classification (AJCC eighth edition) of bone and soft tissue
sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. Jpn J Clin
Oncol. 49:103–107. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tao J, Zhang J, Ling Y, McCall CE and Liu
TF: Mitochondrial Sirtuin 4 resolves immune tolerance in monocytes
by rebalancing glycolysis and glucose oxidation homeostasis. Front
Immunol. 9:4192018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xie Z, Chen W, Chen Y, Wang X, Gao W and
Liu Y: miR-768-3p is involved in the proliferation, invasion and
migration of non-small cell lung carcinomas. Int J Oncol.
51:1574–1582. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
van Solingen C, de Boer HC, Bijkerk R,
Monge M, van Oeveren-Rietdijk AM, Seghers L, de Vries MR, van der
Veer EP, Quax PH, Rabelink TJ and van Zonneveld AJ: MicroRNA-126
modulates endothelial SDF-1 expression and mobilization of
Sca-1(+)/Lin(−) progenitor cells in ischaemia. Cardiovasc Res.
92:449–455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bartel DP: MicroRNA: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2009. View Article : Google Scholar
|
|
28
|
Wang J, Chen J and Sen S: MicroRNA as
biomarkers and diagnostics. J Cell Physiol. 231:25–30. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Y, Xu L and Jiang L: miR-1271
promotes non-small-cell lung cancer cell proliferation and invasion
via targeting HOXA5. Biochem Biophys Res Commun. 458:714–719. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ye M and Zhang J and Zhang J, Miao Q, Yao
L and Zhang J: Curcumin promotes apoptosis by activating the
p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer.
Cancer Lett. 357:196–205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Meister J and Schmidt MH: miR-126 and
miR-126*: New players in cancer. ScientificWorldJournal.
10:2090–2100. 2014. View Article : Google Scholar
|
|
32
|
Feng R, Chen X, Yu Y, Su L, Yu B, Li J,
Cai Q, Yan M, Liu B and Zhu Z: miR-126 functions as a tumour
suppressor in human gastric cancer. Cancer Lett. 298:50–63. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hamada S, Satoh K, Fujibuchi W, Hirota M,
Kanno A, Unno J, Masamune A, Kikuta K, Kume K and Shimosegawa T:
miR-126 acts as a tumor suppressor in pancreatic cancer cells via
the regulation of ADAM9. Mol Cancer Res. 10:3–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Erratum: The lncRNA XIST exhibits
oncogenic properties via regulation of miR-449a and Bcl-2 in human
non-small cell lung cancer. Acta Pharmacol Sin. 38:4432017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lim S and Kaldis P: Cdks, cyclins and
CKIs: Roles beyond cell cycle regulation. Development.
140:3079–3093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schwartz GK and Shah MA: Targeting the
cell cycle: A new approach to cancer therapy. J Clin Oncol.
23:9408–9421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Waldman T, Kinzler KW and Vogelstein B:
p21 is necessary for the p53-mediated G1 arrest in human cancer
cells. Cancer Res. 55:5187–5190. 1995.PubMed/NCBI
|
|
38
|
Kim EM, Jung CH, Kim J, Hwang SG, Park JK
and Um HD: The p53/p21 complex regulates cancer cell invasion and
apoptosis by targeting Bcl-2 family proteins. Cancer Res.
77:3092–3100. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Karimian A, Ahmadi Y and Yousefi B:
Multiple functions of p21 in cell cycle, apoptosis and
transcriptional regulation after DNA damage. DNA Repair (Amst).
42:63–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dutto I, Tillhon M, Cazzalini O, Stivala
LA and Prosperi E: Biology of the cell cycle inhibitor p21(CDKN1A):
Molecular mechanisms and relevance in chemical toxicology. Arch
Toxicol. 89:155–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zavadil J, Haley J, Kalluri R, Muthuswamy
SK and Thompson E: Epithelial-mesenchymal transition. Cancer Res.
68:9574–9577. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
